Nutcracker Therapeutics Moves to Strengthen Leadership Team with Appointment of Experienced HR Executive Angela Peters as Chief Human Resources Officer

Nutcracker Therapeutics, Inc., a biotechnology company committed to developing groundbreaking RNA therapies through its cutting-edge platform, has tapped Angela Peters as its inaugural Chief Human Resources Officer (CHRO). Peters’ appointment comes as the company continues to expand its therapeutic operations, having recently added several high-level executives to its leadership team. With Peters at the helm, Nutcracker Therapeutics is well-positioned to take its ambitions to the next level.

I am thrilled to be joining Nutcracker, an innovative company with a remarkable culture of discovery. I am especially excited to join the team as we unlock the powerful potential of RNA therapeutics. I am committed to giving my colleagues the support they need to do the best work of their careers and make a meaningful difference in the lives of patients.

Nutcracker is delighted to announce the addition of Stephanie Peters to its leadership team as Chief Human Resources Officer. Peters joins from Standard Biotools, formerly Fluidigm, where she was instrumental in transforming HR services and functions through a global and digital transformation. She also helped the company move beyond its single cell genomics roots and become a high-plex imaging pioneer, building talent and cultural initiatives to enhance diversity, equity, and inclusion. Nutcracker looks forward to the valuable contributions and insights she will bring to the team.

Angela boasts a wealth of experience and an impressive track record of strengthening and revolutionizing internal operations in the biotech world. We are thrilled to have her join us as we continue to expand and develop our company. Igor Khandros, CEO, recognizes her immense value and knows her presence will be a significant asset.

Peters brings a wealth of experience to Standard Biotools, having served as a senior director of HR at Medivation (acquired by Pfizer) and associate vice president of HR at Thermo Fisher Scientific. She obtained her bachelor’s degree in marketing from Notre Dame University and further advanced her HR knowledge through the University of California Berkeley extension program for chief HR officers. Now, Peters is committed to helping Standard Biotools grow and reach its full potential.

In the past year, Vynca has added several key members to its C-suite team, including Chief Medical Officer Dr. Robert Schott, Chief Operating Officer Dr. John Stubenrauch, Chief Business Officer Dr. Geoff Nosrati, and now Chief Revenue Officer George Peters. With these experienced professionals at the helm, Vynca is well-positioned for continued success.

About Nutcracker Therapeutics, Inc.

Nutcracker Therapeutics, Inc. is revolutionizing the field of RNA therapeutics with its advanced engineering and high-precision biosynthesis capabilities. By combining the power of their complete RNA platform with the support of clinical investigators from leading institutions, Nutcracker Therapeutics has the potential to reduce development costs and time for RNA medicines. This cutting-edge technology offers a faster and more efficient approach to RNA manufacturing, providing a distinct advantage in speed and scalability over existing methods.

Leave a Comment